Bullfrog AI Holdings, Inc. BFRG shares are trading higher Tuesday after the company announced data from a preclinical study evaluating a novel prodrug of mebendazole for the treatment of glioblastoma.
The Details:
Bullfrog AI announced positive data resulting from a preclinical study on a novel formulation of mebendazole and a novel prodrug of mebendazole, compared with placebo in mice that had been implanted with tumor cells.
Vin Singh, CEO of BullFrog AI, stated, "This is the first study to demonstrate that BF-223, a novel mebendazole prodrug, has anti-cancer activity in animals."
Bullfrog AI shares are up on very heavy trading volume. According to data from Benzinga Pro, more than 8 million shares have already been traded in the session, compared to the stock's 100-day average of 1.072 million shares.
Related News: What's Going On With Sea Limited Stock?
BFRG Price Action: According to Benzinga Pro, Bullfrog AI Holdings shares are up 28.2% at $3.68 at the time of publication.
Image: Clker-Free-Vector-Images from Pixabay
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
